RBC Lowers Evommune Price Target to $21.00

Royal Bank of Canada (RBC) has lowered its price target for Evommune (NYSE:EVMN) to $21.00 from $29.00, citing a potential upside of 88.59% from the stock's previous close.

The firm currently has an 'outperform' rating on the stock and is among several analysts that have issued reports on EVMN in recent weeks.

Other research analysts who have recently weighed in on Evommune include William Blair, HC Wainwright, Morgan Stanley, Wall Street Zen, and Raymond James Financial.